(CBMG) |
| 0 (0%) 04-14 18:29 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 41.22 |
| Resistance 1: | 35.29 |
| Pivot price: | 33.03 |
| Support 1: | 32.39 |
| Support 2: | 30.60 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 1.140 |
| Book Value | 2.170 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.677 |
| Profit Margin (%) | 12.88 |
| Operating Margin (%) | 15.21 |
| Return on Assets (ttm) | 13.9 |
| Return on Equity (ttm) | 47.3 |
Company news
Tue, 07 Apr 2026
CBMG New Materials (02439.HK) revises its IPO placement price to HKD 0.23 and resumes trading on Wednesday. - 富途牛牛
Tue, 20 Jan 2026
AstraZeneca pays $630m to get full control of AbelZeta CAR-T - pharmaphorum
Mon, 19 Jan 2026
AstraZeneca goes all-in on AbelZeta’s Car | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Wed, 03 May 2023
Janssen Biotech signs licence deal with CBMG for CAR-T cancer therapies - Pharmaceutical Technology
Wed, 03 May 2023
May 2 Quick Takes: Janssen paying CBMG $245M for CAR T rights - biocentury.com
Wed, 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - BioSpace
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
